Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma
Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.
Video Player is loading.
EP: 1.Goals of Therapy and Treatment Options for Patients with Transplant-Ineligible NDMM
EP: 2.Clinical Implications from the MAIA and SWOG S0777 Studies
EP: 3.Assessing and Supporting Frail Patients with NDMM
EP: 4.Implementing Real-world Evidence into Clinical Practice in NDMM
EP: 5.Optimizing Treatment Duration and Adverse Effect Management in Patients with NDMM
Now Viewing
EP: 6.Addressing Unmet Needs and Disparities Across Patient Populations in Multiple Myeloma
EP: 7.Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Recent Videos
Future of HER2-Directed Tumor-Agnostic Therapies
Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage
Review of Current Landscape of HER2-Directed Tumor-Agnostic Therapies
Updates and Clinical Implications of DESTINY-Lung02 and DESTINY-Lung03 Trials
HER2 Key Differences and Current Approaches to Biomarker Testing
Introduction to HER2-Directed Tumor-Agnostic Approaches
Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
R/R MM Treatment Landscape: Role of Bispecifics
Future Perspectives in R/R MM
Bispecifics in R/R MM: AE Management and Sequencing
Related Content
